Supporting the

Neuroendocrine Cancer Community

Prevalence of self-reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues

Aug 3, 2021

A publication on the prevalence of self-reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues written by Catherine Bouvier, Tara Whyand and Philippa Davies was featured in the British Journal of Nursing in 2018.
 
Somatostatin analogues (SSA) are a common treatment for some forms of neuroendocrine tumours (NETs). Patients report a variety of side effects after starting these drugs, so in most cases they require a lot of nutritional input. An online survey was used to invite responses from patients worldwide to determine the extent of reported side effects. Patients were asked which SSA they were taking and how they rated the severity of their side effects.
 
The survey found that many self‐reported side effects from the use of SSAs were experienced more frequently than previous clinical studies or the patient information leaflets reported.